Household goods & home construction
Reckitt is a global consumer-health and hygiene group whose major brands include Dettol, Durex, Finish, Nurofen, Strepsils, Gaviscon and Lysol. Following portfolio disposals it is increasingly focused on higher-growth health and hygiene brands.
Manufacture and marketing of health, hygiene and nutrition products, including over-the-counter medicines, disinfectants, household products, sexual wellness and infant nutrition.
Global consumer markets, with major operations in North America, Europe and emerging markets including India and China.
Brand growth, pricing and volumes, product innovation, emerging-market demand, gross margins, advertising efficiency, portfolio simplification and share buybacks.
Product liability, regulation, competition from private labels, commodity and packaging inflation, foreign exchange, infant-formula litigation and execution of portfolio changes.
29 July 2026: Core Reckitt Q2 like-for-like revenue grew 4.2%, accelerating H1 growth to 2.7%, and management reiterated 4-5% full-year Core growth guidance. A new buyback of up to £500m was announced, while investors should continue to monitor Mead Johnson litigation and the benefits of the simplified portfolio.
Reckitt targets sustainable ordinary dividend growth and also uses buybacks and specials. The 2026 interim dividend is 88.6p per share, up 5%; shareholders also received a £1.6bn special dividend in February 2026 following the Essential Home disposal.
The complete 350 Trade Book — 350 leading UK-listed companies, presented in one consistent working reference.